Calliditas Therapeutics AB
www.calliditas.se/en/
Latest From Calliditas Therapeutics AB
Interview: The Pace Quickens For Calliditas's Berger's Disease Candidate
A Phase III trial design change could result in quicker patient access for Calliditas’s product candidate for Berger’s disease, and boost the growth potential for the Swedish biotech.
Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease
Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US
Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.
Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Renal System
- Alias(es)
- Pharmalink AB
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Scandinavia
-
Sweden
-
Sweden
-
Scandinavia
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Calliditas Therapeutics AB
- Senior Management
-
Renee Aguiar-Lucander, CEO
Fredrik Johansson, CFO
Jens Kristensen, PhD, CMO - Contact Info
-
Calliditas Therapeutics AB
Phone: (46) 8 411 3005
Wallingatan 26B
Stockholm, SE-114 24
Sweden
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice